In 2014, the U.S. Food and Drug Administration (FDA) issued a safety warning regarding procedures involving laparoscopic power morcellation. The decision was made after a review of scientific literature revealed that 1 in 350 women that underwent surgeries using power morcellators had developed uterine sarcomas, which are malignant tumors. In response, many women and their families have filed
You trust your doctor to prescribe an FDA-approved medication when you ask them for help with a treatable health problem. However, what you may not know is that one in five prescriptions treat something that the drug was not labeled or approved to treat. This is called off-label usage, and the companies producing said drugs—in order
Power morcellators—surgical tools approved by the FDA and released into the market in the 1990s—provide doctors with a minimally invasive way to break up and remove uterine fibroids and perform hysterectomies. Yet in recent years, these devices have also been linked to increased cancer risks because they can potentially distribute cancerous uterine cells throughout the body.
The blood thinner Xarelto is approved by the FDA to reduce the risk of blood clots in patients who have undergone surgery or experienced hemorrhagic strokes, thrombotic strokes, Pulmonary Embolism (PE), and Deep Vein Thrombosis (DCVT). While this medication is effective for aiding in these situations, it carries with it a serious possible side effect. Xarelto bleeding risks have been
According to the latest AndroGel lawsuit updates, the legal teams involved are currently in the process of selecting cases for the upcoming bellwether trials anticipated in the fall of next year. These trials will test more than 2,000 claims that the health risks associated with AndroGel, a gel used in testosterone replacement therapy, were not fully disclosed to patients. Once cases